GRAPE KING BIO LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 156.5 TWD | +0.32% |
|
+0.97% | +0.32% |
| Feb. 27 | Grape King Bio Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 09 | Grape King Bio Hits Record-High Sales of NT$10.64 Billion in 2023 | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 26,526 | 24,191 | 23,702 | 24,887 | 23,109 | 23,183 | - |
| Enterprise Value (EV) 1 | 25,629 | 23,270 | 20,277 | 20,097 | 18,362 | 18,446 | 18,329 |
| P/E ratio | 20.2 x | 19.1 x | 18.3 x | 17.2 x | 16 x | 14.8 x | 14.6 x |
| Yield | 3.33% | 3.61% | 3.81% | 4.11% | 3.91% | 4.56% | 4.72% |
| Capitalization / Revenue | 2.87 x | 2.64 x | 2.42 x | 2.4 x | 2.17 x | 2.01 x | 1.92 x |
| EV / Revenue | 2.77 x | 2.54 x | 2.07 x | 1.93 x | 1.73 x | 1.6 x | 1.52 x |
| EV / EBITDA | 9.66 x | 8.56 x | 7.4 x | 6.7 x | 6.21 x | 5.84 x | 5.49 x |
| EV / FCF | 16.6 x | 15.5 x | 8.94 x | 8.03 x | 9.5 x | 11.9 x | 10.5 x |
| FCF Yield | 6.01% | 6.47% | 11.2% | 12.5% | 10.5% | 8.38% | 9.54% |
| Price to Book | 4.3 x | 3.65 x | 2.63 x | 2.6 x | 2.32 x | 2.2 x | 1.85 x |
| Nbr of stocks (in thousands) | 136,032 | 136,286 | 148,137 | 148,137 | 148,137 | 148,137 | - |
| Reference price 2 | 195.0 | 177.5 | 160.0 | 168.0 | 156.0 | 156.5 | 156.5 |
| Announcement Date | 2/24/20 | 2/26/21 | 2/24/22 | 2/23/23 | 2/27/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 9,239 | 9,168 | 9,798 | 10,391 | 10,635 | 11,529 | 12,070 |
| EBITDA 1 | 2,654 | 2,720 | 2,739 | 3,001 | 2,956 | 3,159 | 3,340 |
| EBIT 1 | 2,335 | 2,305 | 2,312 | 2,552 | 2,497 | 2,721 | 2,770 |
| Operating Margin | 25.27% | 25.14% | 23.59% | 24.56% | 23.47% | 23.6% | 22.95% |
| Earnings before Tax (EBT) 1 | 2,440 | 2,378 | 2,415 | 2,688 | 2,661 | 2,898 | 3,023 |
| Net income 1 | 1,309 | 1,272 | 1,300 | 1,457 | 1,453 | 1,599 | 1,670 |
| Net margin | 14.17% | 13.87% | 13.27% | 14.02% | 13.66% | 13.87% | 13.84% |
| EPS 2 | 9.630 | 9.290 | 8.760 | 9.780 | 9.740 | 10.57 | 10.74 |
| Free Cash Flow 1 | 1,541 | 1,505 | 2,267 | 2,504 | 1,932 | 1,545 | 1,749 |
| FCF margin | 16.68% | 16.42% | 23.14% | 24.09% | 18.17% | 13.4% | 14.49% |
| FCF Conversion (EBITDA) | 58.07% | 55.35% | 82.77% | 83.42% | 65.36% | 48.91% | 52.36% |
| FCF Conversion (Net income) | 117.73% | 118.35% | 174.33% | 171.83% | 133.01% | 96.64% | 104.73% |
| Dividend per Share 2 | 6.500 | 6.400 | 6.100 | 6.900 | 6.100 | 7.143 | 7.385 |
| Announcement Date | 2/24/20 | 2/26/21 | 2/24/22 | 2/23/23 | 2/27/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,404 | 2,919 | 2,053 | 2,722 | 2,492 | 3,124 | 2,220 | 2,665 | 2,551 | 3,200 | 2,384 | 2,882 | 2,813 | 3,554 |
| EBITDA | 684.7 | 875.6 | - | 780.4 | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 578 | 767.7 | 421.8 | 668.4 | 639 | 822.5 | 478.2 | 562.1 | 634 | 822.3 | 501.3 | 643 | 683.7 | 944 |
| Operating Margin | 24.05% | 26.3% | 20.55% | 24.55% | 25.64% | 26.33% | 21.54% | 21.09% | 24.86% | 25.69% | 21.03% | 22.31% | 24.3% | 26.56% |
| Earnings before Tax (EBT) 1 | 605.7 | 802 | 447.8 | 701.5 | 672.1 | 866.4 | 510.6 | 606.4 | 681.4 | 862.2 | 529.7 | 675 | 717.3 | 976 |
| Net income 1 | 302 | 440 | 235.7 | 385 | 364.8 | 471.5 | 279.8 | 337.9 | 366.7 | 468.3 | 284.7 | 374.3 | 392.7 | 547 |
| Net margin | 12.57% | 15.08% | 11.48% | 14.14% | 14.64% | 15.09% | 12.6% | 12.68% | 14.38% | 14.63% | 11.94% | 12.99% | 13.96% | 15.39% |
| EPS 2 | 2.030 | 2.950 | 1.580 | 2.590 | 2.450 | 3.160 | 1.880 | 2.280 | 2.470 | 3.130 | 1.923 | 2.523 | 2.650 | 3.693 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 2/24/22 | 5/12/22 | 8/11/22 | 11/8/22 | 2/23/23 | 5/10/23 | 8/10/23 | 11/10/23 | 2/27/24 | - | - | - | - |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 897 | 921 | 3,425 | 4,790 | 4,748 | 4,737 | 4,855 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 1,541 | 1,505 | 2,267 | 2,504 | 1,932 | 1,545 | 1,749 |
| ROE (net income / shareholders' equity) | 22% | 19.9% | 16.7% | 15.7% | 14.9% | 14.1% | 14.6% |
| ROA (Net income/ Total Assets) | 11.9% | 10.4% | 9.57% | 10% | 9.51% | 13.5% | 16.7% |
| Assets 1 | 11,004 | 12,231 | 13,582 | 14,557 | 15,282 | 11,886 | 10,000 |
| Book Value Per Share 2 | 45.40 | 48.60 | 60.90 | 64.60 | 67.40 | 71.10 | 84.40 |
| Cash Flow per Share 2 | 15.90 | 19.90 | 17.10 | 20.10 | 17.00 | 14.20 | 13.20 |
| Capex 1 | 630 | 1,214 | 275 | 487 | 587 | 553 | 563 |
| Capex / Sales | 6.82% | 13.24% | 2.81% | 4.68% | 5.52% | 4.8% | 4.66% |
| Announcement Date | 2/24/20 | 2/26/21 | 2/24/22 | 2/23/23 | 2/27/24 | - | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
156.5
TWD
Average target price
172.8
TWD
Spread / Average Target
+10.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.32% | 711M | |
| +8.20% | 7.78B | |
| +0.34% | 7.38B | |
| +10.20% | 6.52B | |
| -8.10% | 3.67B | |
| -13.13% | 3.44B | |
| -14.57% | 1.17B | |
| +8.34% | 934M | |
| -42.27% | 879M | |
| -18.90% | 836M |
- Stock Market
- Equities
- 1707 Stock
- Financials Grape King Bio Ltd
